Six years after the Boehringer Inhelheim and Eli Lilly Alliance, four new medications have integrated to help the control of diabetes, and this 2017 is added oral wallpaper, which eliminates surplus sugar through urine and does not damage the heart.
A patient with poorly controlled diabetes becomes 300% more expensive than one controlled, and at least 70% of diabetes deaths are directly related to cardiovascular failures, and that is that a diabetic patient who does not carry good control of his glucose canPresent a heart attack, cerebrovascular event, peripheral and renal vascular, Dr. Gustavo Rojas, internist cardiologist at the National Institute of Cardiology (INC).
“Pagliflozine facilitates the elimination of more glucose through the urine next to a series of associated calories.The benefit of heart protection has never been seen in an oral antidiabetic, which undoubtedly implies a change of focus that must be considered as watershed in the clinical treatment guides, ”he said at a press conference.
The specialist reported that worldwide the attention of diabetic complications amounted to 673,000 million dollars;that is, 12% of the global health expense.While in Mexico costs exceeding 7,000 million dollars have been reported.
Pagliflozine is available since 2014 to improve glycemic control in adults with DM2 and at the end of 2016 it received its second approval in record time by the main regulatory agencies in the world as the United States Food and Medicines Agency (FDA), theEuropean Medicines Agency (EMA) and the Federal Commission for Protection against Health Risks (COFEPRIS) of Mexico due to the positive results of the clinical trial in which more than 7,000 patients, from 42 countries, participated with cardiovascular diseases.
The treatment is of medical prescription and must be accompanied by balanced diet and exercise, to achieve optimal control of glucose or blood sugar levels and the other benefits related to cardiovascular health.
Margarita Zamora, Medical Advisor in Endocrinology of Eli Lilly, clarified that the alliance with BI is at least 20 years, “we are the strongest alliance in the diabetes area, we have launched four oral medications with their respective combinations.The commitment is to continue investigating to bring innovation, this alliance goes for long. ”
In 2016, Sanofi and Bi internationals signed an international strategic exchange, where the French ceded to BI her area of mereal animal health, and the German yielded to Sanofi her portfolio of self -care of human health (OTC), in Mexico the operation the operationIt was approved by the Federal Economic Competition Commission (Cofece), with the condition that BI would have to keep the cough syrup portfolio, to avoid competition conflicts.In animal health, four vaccines will also have to be sold later by BI.
